A Phase II, Double-Blind, Randomized, Controlled Trial to Assess the Safety and Immunogenicity of a Tetravalent Dengue Vaccine With Two Different Serotype 2 Potencies in an Adult Population in Singapore
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 14 Jun 2017
At a glance
- Drugs TAK 003 (Primary)
- Indications Dengue
- Focus Pharmacodynamics
- Sponsors Takeda
- 31 Aug 2016 Status changed from recruiting to active, no longer recruiting.
- 07 Jul 2016 Planned End Date changed from 1 Aug 2016 to 1 Aug 2017.
- 07 Jul 2016 Planned primary completion date changed from 1 Aug 2016 to 1 Aug 2017.